Senior Product Manager - Enterprise Solutions

Omada Health CEO Sean Duffy sold 31,457 shares on 1 September 2026, according to an SEC filing. The transaction was valued at approximately $735,150, with shares sold at a weighted average price of $23.37. Of the total, 21,572 shares were sold on the open market, whilst 9,885 shares were used to satisfy tax withholding obligations related to vesting equity awards. The entire transaction was executed under a Rule 10b5-1 trading plan established on 13 March 2026. Following the sale, Duffy holds approximately 1.3 million shares of common stock directly and through family trusts, plus 512,994 outstanding options. The company, which provides virtual care programmes for chronic disease management, reported $309.80 million in revenue and $4.30 million in net income on a trailing twelve-month basis.

Omada Health reported record second-quarter revenue of $88 million, up 43% year-over-year and 13% sequentially. The digital health company achieved GAAP net income of more than $5 million, compared with a net loss of approximately $5 million in the same quarter last year. Gross margin reached 73% on a GAAP basis, up from 66% in the prior-year quarter. Adjusted EBITDA was approximately $11 million, marking a quarterly record and an $11 million improvement year-over-year. Total members grew 45% year-over-year to approximately 1.1 million, driven by broad enrollment growth across its cardiometabolic programmes. The company raised its full-year revenue guidance to $334 million to $340 million, up from previous guidance of $322 million to $330 million. Adjusted EBITDA guidance was increased to $21 million to $27 million.

Omada Health appoints Wei-Li Shao as new CEO as company ramps up GLP-1 strategy. Omada Health announced a leadership shift as Wei-Li Shao, who currently serves as president, will become CEO, effective January 1. Sean Duffy, founder and CEO, will transition to founder and executive chair, supporting Shao and the Board on Omada Health's long-term mission, key partnerships and strategic initiatives, the company announced Thursday in conjunction with its second-quarter earnings results. Shao joined Omada Health in 2019 as chief commercial officer and was appointed president in 2021. As president, he has held "direct accountability for Omada Health's P&L and full operating agenda, leading the product, commercial and operational strategy that scaled the company from a single-condition program into a multi-condition care platform," the company said in a press release. "He built the long-range plan that guides how Omada Health runs today and has been a close strategic partner to Sean throughout the company's growth," management said. Prior to Omada Health, Shao spent 18 years at Eli Lilly and Company, where he held senior leadership roles across its global healthcare and biopharmaceutical businesses, including experience in the cardiometabolic and diabetes markets, which align with Omada Health's business focus. "Over the past seven years, Wei-Li and I have worked together to build a strong company as Wei-Li has steadily increased his scope of responsibility. His track record of delivering innovation, commercial wins, and strong financial growth has shaped Omada and demonstrates that Wei-Li is the right leader to take Omada to the next level of impact and scale," Duffy said in a statement. "Fifteen years ago, Sean designed an innovative solution to help Americans bridge the healthcare gap. Together, we've shown the model works, yet I believe our biggest impact is still ahead. Our results serve as a foundation to raise our ambitions. Now is the time to scale, push harder on our mission, and bend the curve of chronic disease," Shao said in a statement. The virtual care provider reported strong growth driven by demand for its integrated approach to managing chronic conditions such as diabetes, hypertension, obesity and musculoskeletal disorders. The company continues to expand its portfolio of multiple chronic condition programs for its existing customer base of employers and health plans, while also broadening its commercial reach through its GLP-1 capabilities and new cholesterol care track. Omada Health, which went public in June, ties remote monitoring devices with coaching and artificial intelligence to help consumers control their chronic diseases. The company supports diabetes, hypertension, cholesterol, obesity and musculoskeletal conditions and leans on its multi-condition approach to differentiate itself from competitors. The company works with more than 2,000 employers and health plans today. "We just reported our strongest quarter ever, reaching a record number of members and our highest revenue and gross margin to date, with more than 2 million lifetime members served, commercial relationships with the nation's three leading PBMs (pharmacy benefit managers) and a proven and profitable model," Duffy told investors and analysts on the Q2 earnings call. Omada Health's membership grew 45% year-over-year, "reflecting continued demand across Omada Health's integrated cardiometabolic care platform and strong enrollment momentum across diabetes and hypertension programs," management said in a press release on its Q2 results. The company brought in revenue of $88 million in Q2, up 43% from $61 million the same period a year ago, and reported profit of $5 million, compared with a net loss of $5 million in Q2 2025. Omada Health's adjusted EBITDA in the quarter was $11 million, compared with an adjusted EBITDA loss of $200,000 a year ago. The company reported gross margin of 73% in the second quarter, up from 66% in Q2 2025. "This marks Omada Health's most profitable quarter to date, both in absolute terms and on a margin basis, demonstrating continued operating leverage," said Steve Cook, Omada Health's chief financial officer, in a statement. "At the midpoint, our raised full-year outlook represents approximately 30% year-over-year revenue growth and a fourfold increase in adjusted EBITDA, reflecting our extraordinary second-quarter performance and our path of sustainable profitability." The company highlighted recent milestones including an expanded partnership with Health Care Services Corporation that extends its prevention and weight health and hypertension management programs across HCSC's fully insured book of business in Illinois, Oklahoma, and New Mexico, reaching an additional 1.5 million covered lives. In February, the company announced its Omada for Cholesterol program to bring its artificial-intelligence-powered and human-led coaching approach to cholesterol management and embed it within the broader platform for managing weight, blood pressure and diabetes. The company announced the first deployment of its cholesterol management offering in July, expanding personalized multi-condition care for employees of one of the nation's largest retailers, management said. In May, the company announced it had signed on with Optum Rx to participate in its Weight Engage program, marking the company's first offering of prescribing capabilities within a pharmacy benefit manager channel. During Q2, the company closed its first customer for the prescribing program and management expects that program to yield revenue in 2027, signaling early market demand and future revenue potential. "Our outstanding second quarter reflects the strength of our strategy, the momentum we've built across the business, and the exceptional team driving Omada forward," Duffy said. "Reflecting continued demand for our integrated between-visit care platform, total members increased 45% year over year as we expanded our commercial channels, deepened relationships with our leading PBM channels, and introduced our cholesterol management program with one of the nation's largest retailers. The opportunity ahead is significant, and we'll remain focused on disciplined execution as we look to broaden our capabilities, deepen customer relationships and improve the health of even more members." Omada Health hiked its 2026 outlook and is now forecasting revenue in the range of $334 million to $340 million, with the midpoint representing 30% growth compared with 2025. This range is up from the prior range of $322 million to $330 million. The company projects adjusted EBITDA in the range of $21 million to $27 million, with the midpoint representing a four times increase compared with 2025, and this range is up from the prior range of $14 million to $20 million. Editor's Note: This is a developing story and will be updated following the Q2 earnings call. Let Google know we are your trusted source. Add our editorial as a preferred source in your search results.